Agios Pharmaceuticals Inc. has announced a strategic partnership with Avanzanite Bioscience B.V., a specialty pharmaceutical company focused on rare disease medicines in Europe. The agreement grants Avanzanite the commercialization and distribution rights for PYRUKYND® (mitapivat), a pyruvate kinase activator approved for adults with PK deficiency, across the European Economic Area, the UK, and Switzerland. This partnership aims to enhance patient access to rare disease therapies without the need for costly local infrastructure. Avanzanite plans to expand into 32 European countries over the next year, continuing its mission to ensure no patient is left behind.